Published in J Biol Chem on July 19, 2011
Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab (2012) 2.25
Retracted Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling. J Neuroinflammation (2014) 1.63
Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience (2012) 1.58
Microglia development and function. Annu Rev Immunol (2014) 1.41
Microglia, seen from the CX3CR1 angle. Front Cell Neurosci (2013) 1.30
Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front Cell Neurosci (2014) 1.12
The brain's best friend: microglial neurotoxicity revisited. Front Cell Neurosci (2013) 1.09
The ischemic environment drives microglia and macrophage function. Front Neurol (2015) 1.09
Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation (2014) 0.99
SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci (2015) 0.98
Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun (2015) 0.97
Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain (2015) 0.96
Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles. Prog Neurobiol (2014) 0.94
Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol (2012) 0.93
Tackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system. Stem Cell Res Ther (2013) 0.92
The biphasic role of microglia in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.91
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci (2012) 0.91
The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology (2014) 0.91
Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm (2013) 0.90
IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology. J Neuroinflammation (2014) 0.88
Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm (2014) 0.87
The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol Biol (2013) 0.87
Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol (2014) 0.86
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends Neurosci (2015) 0.85
Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases. Int J Alzheimers Dis (2012) 0.85
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke (2012) 0.84
Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathol (2014) 0.84
The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease. Sultan Qaboos Univ Med J (2015) 0.84
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy. J Clin Cell Immunol (2014) 0.83
Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury. J Neuroinflammation (2015) 0.83
From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res Rev (2013) 0.83
Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and Tau-related pathologies. Am J Pathol (2013) 0.82
Transgenic increase in n-3/n-6 fatty acid ratio protects against cognitive deficits induced by an immune challenge through decrease of neuroinflammation. Neuropsychopharmacology (2014) 0.82
When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration? J Neuroimmune Pharmacol (2012) 0.81
Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease. PLoS One (2015) 0.81
Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina. ASN Neuro (2015) 0.81
HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-κBYY1 pathway. Curr HIV Res (2014) 0.80
Fractalkine Signaling and Microglia Functions in the Developing Brain. Neural Plast (2015) 0.80
Central Nervous System: (Immunological) Ivory Tower or Not? Neuropsychopharmacology (2016) 0.79
Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models. Exp Neurol (2013) 0.79
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Therapeutic Potential of Dental Pulp Stem Cell Secretome for Alzheimer's Disease Treatment: An In Vitro Study. Stem Cells Int (2016) 0.79
Is membrane homeostasis the missing link between inflammation and neurodegenerative diseases? Cell Mol Life Sci (2015) 0.78
Microglia communication: Parallels between aging and Alzheimer's disease. Clin Exp Neuroimmunol (2016) 0.78
CX3CR1 deficiency delays acute skeletal muscle injury repair by impairing macrophage functions. FASEB J (2015) 0.78
G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. Front Aging Neurosci (2016) 0.78
Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid β-Protein Oligomers. J Neurosci (2016) 0.77
The evolving biology of microglia in Alzheimer's disease. Neurotherapeutics (2015) 0.77
Microglia Ontology and Signaling. Front Cell Dev Biol (2016) 0.77
Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease. Mol Neurobiol (2016) 0.76
Fractalkine Receptor Deficiency Is Associated with Early Protection but Late Worsening of Outcome following Brain Trauma in Mice. J Neurotrauma (2015) 0.76
Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity. PLoS One (2015) 0.76
A novel method for gathering and prioritizing disease candidate genes based on construction of a set of disease-related MeSH® terms. BMC Bioinformatics (2014) 0.76
Knockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected mice. J Gen Virol (2016) 0.76
Role of Atypical Chemokine Receptors in Microglial Activation and Polarization. Front Aging Neurosci (2017) 0.76
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection. Biomed Res Int (2016) 0.75
Complex Roles of Microglial Cells in Ischemic Stroke Pathobiology: New Insights and Future Directions. Int J Mol Sci (2017) 0.75
Old Maids: Aging and Its Impact on Microglia Function. Int J Mol Sci (2017) 0.75
Fractalkine signaling in regulation of insulin secretion. Islets (2014) 0.75
Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. Mol Autism (2017) 0.75
Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Mol Neurobiol (2016) 0.75
The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity. Front Aging Neurosci (2017) 0.75
The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices. J Neuroinflammation (2017) 0.75
Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol Neurodegener (2017) 0.75
Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders. Transl Psychiatry (2017) 0.75
Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol (2000) 14.74
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Recognition memory: what are the roles of the perirhinal cortex and hippocampus? Nat Rev Neurosci (2001) 7.25
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol (2009) 6.79
Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 6.70
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
Recognition memory and the medial temporal lobe: a new perspective. Nat Rev Neurosci (2007) 5.74
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A (1998) 5.15
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci (2007) 3.93
Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci (2008) 3.90
The myeloid cells of the central nervous system parenchyma. Nature (2010) 3.80
SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem (2005) 3.38
Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol (2009) 3.04
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci (2006) 2.22
Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A (2000) 2.20
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia (2000) 1.88
CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J Neurosci (2010) 1.88
Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res (2003) 1.87
Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem (1998) 1.64
Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem (2001) 1.58
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging (1997) 1.56
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology (2010) 1.51
Interleukin-6: a cytokine to forget. FASEB J (2004) 1.45
Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res (2004) 1.36
Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol (2005) 1.30
The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci (2009) 1.26
Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J (1997) 1.18
Impaired bidirectional synaptic plasticity and procedural memory formation in striatum-specific cAMP response element-binding protein-deficient mice. J Neurosci (2006) 1.18
Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett (1995) 1.06
Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci (2004) 1.03
Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience (2003) 0.89
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 5.84
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem (2005) 3.38
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One (2010) 3.24
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron (2006) 2.88
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci (2009) 2.71
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron (2008) 2.44
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum (2007) 2.42
NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci (2010) 2.41
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc (2006) 2.08
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A (2006) 2.07
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
New non-viral method for gene transfer into primary cells. Methods (2004) 2.00
The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2011) 1.96
Astrocyte influences on ischemic neuronal death. Curr Mol Med (2004) 1.92
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
Natalizumab and PML. Nat Neurosci (2005) 1.85
GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell (2009) 1.84
Microglial activation in stroke: therapeutic targets. Neurotherapeutics (2010) 1.84
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood (2011) 1.82
p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol (2003) 1.79
The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci (2005) 1.74
Localization of the Slack potassium channel in the rat central nervous system. J Comp Neurol (2002) 1.74
The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 1.73
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol (2002) 1.70
A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol (2002) 1.69
Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Cell Stem Cell (2009) 1.68
CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci (2010) 1.65
Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol (2007) 1.63
Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci (2011) 1.59
Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol (2006) 1.59
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Microgliosis: the questions shape the answers. Nat Neurosci (2007) 1.51
Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron (2008) 1.49
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol (2007) 1.45
Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol (2005) 1.45
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci (2010) 1.44
Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J (2010) 1.44
Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci U S A (2012) 1.43
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J (2011) 1.40
VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol (2004) 1.39
Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol (2011) 1.35
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics (2007) 1.34
Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest (2012) 1.34
Defining interferon beta response status in multiple sclerosis patients. Ann Neurol (2004) 1.34
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci (2007) 1.31
Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev (2012) 1.30
Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J (2009) 1.30
Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods (2009) 1.29
Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J Neurosci (2010) 1.28
Monocytes regulate T cell migration through the glia limitans during acute viral encephalitis. J Virol (2010) 1.27
CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol (2004) 1.26
Recurrent varicella zoster virus myelopathy. J Neurol Sci (2008) 1.26
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J Leukoc Biol (2008) 1.25
Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res (2002) 1.23
A protective role for ELR+ chemokines during acute viral encephalomyelitis. PLoS Pathog (2009) 1.23
The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol (2004) 1.23
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflammation (2012) 1.22